Studies on biodegradable polymeric nanoparticles of risperidone: In vitro and in vivo evaluation

Nanomedicine

Volumn 3, Issue 3, 2008, Pages 305-319

  Muthu, Madaswamy S ^a   Singh, Sanjay ^b  

^a BANARAS HINDU UNIVERSITY   (India)

^b BANARAS HINDU UNIVERSITY   (India)

Author keywords

Electron diffraction ring pattern; In vivo studies; Poly (e caprolactone) nanoparticles; Risperidone

Indexed keywords

APOMORPHINE; NANOPARTICLE; POLOXAMER; POLYCAPROLACTONE; RISPERIDONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIODEGRADABILITY; CATALEPSY; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; EXTRAPYRAMIDAL SYMPTOM; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; POLYMERIZATION; PRECIPITATION; PRIORITY JOURNAL; PSYCHOSIS; X RAY DIFFRACTION;

ABSORBABLE IMPLANTS; ANIMALS; BEHAVIOR, ANIMAL; DIFFUSION; DRUG CARRIERS; DRUG COMPOUNDING; DRUG EVALUATION, PRECLINICAL; INJECTIONS, INTRAVENOUS; MICE; NANOPARTICLES; POLYESTERS; RISPERIDONE;

EID: 45149100702     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/17435889.3.3.305     Document Type: Article

References (41)

1. Gref R, Minamitake Y: Biodegradable long circulating nanospheres. Science 263, 1600-1603 (1994).
2. Labhasetwar V, Song C, Levy RJ: Nanoparticles drug delivery systems. Adv. Drug Deliv. Rev. 24, 63-85 (1997).
3. Sinha VR, Bansal K, Kaushik R et al.: Poly-epsilon-caprolactone microspheres and nanospheres: an overview. Int. J. Pharm. 278, 1-23 (2004).
4. Allemann E, Gurny R, Doelker E: Drug-loaded nanoparticles-preparation methods and drug targeting issues. Eur. J. Pharm. Biopharm. 39, 173-191 (1993).
5. Mainardes RM, Evangelista RC: PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution. Int J. Pharm 290, 137-144 (2005).
6. Pitt CG, Marks TA, Schindler A: Biodegradable drug delivery systems based on aliphatic polyesters: application to contraceptives and narcotic antagonists. NIDA Res. Monog. 28, 232-253 (1981).
7. Sinha VR, Khosla L: Bioabsorbable polymers for implantable therapeutic systems. Drug. Dev. Ind. Pharm. 24, 1129-1138 (1998).
8. Shenoy DB, Amiji MM: Poly (ethylene oxide)-modified poly (ε-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer. Int. J. Pharm. 293, 261-270 (2005).
9. Pitt CG, Gratzl MM, Kimmel GL et al.: Aliphatic polyester II. The degradation of poly (DL-lactide), poly (ε-caprolactone), and their copolymers in vivo. Biomaterials 2, 215-220 (1981).
10. Woodward SC, Brewer PS, Moatamed F et al.: The intracellular degradation of poly (ε-caprolactone). J. Biomed. Mater. Res. 19, 437-444 (1985).
11. Gaur U, Sahoo SK, De TK et al.: Biodistribution of fluoresceinated dextran using novel nanoparticles evading reticuloendothelial system. Int. J. Pharm. 202, 1-10 (2000).
12. Sussman N: Choosing an atypical antipsychotic. Int. Clin. Psychopharmcol. 17, S29-S33 (2002).
13. Ereshefsky L, Lacombe S: Pharmacological profile of risperidone. Can. J. Psychiatry 38, S80-S88 (1993).
14. Budavari S: The Merck Index. Merck & Co., Inc., Whitehouse Station, NJ, USA 13, 1478 (2001).
15. Hardman G, Limbid LE, Gilman AG: The Pharmacological Basis of Therapeutics. McGraw Hill, NY, USA 10, 279(2001).
16. Rabin C, Liang Y, Ehrlichman RS et al.: In vitro and in vivo demonstration of risperidone implants in mice. Schizophr. Res. 98, 66-78 (2008).
17. Ould-Ouali L, Noppe M, Langlois X et al.: Self-assembling PEG-p(CL-co-TMC) copolymers for oral delivery of poorly water-soluble drugs: a case study with risperidone. J. Control. Release 102, 657-668 (2005).
18. Ereshefsky L, Mascarenas CA: Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J. Clin. Psychiatry 64, 18-23 (2003).
19. Vasavan Nair NP, Suranyi-Cadotte B, Schwartz G et al.: A clinical trial comparing intramuscular haloperidol decanoate and oral haloperidol in chronic schizophrenic patients: efficacy, safety; and dosage equivalence. J. Clin. Psychopharmacol. 6, S30-S37 (1986).
20. Aravagiri M, Yuwiler A, Marder S: Distribution after repeated oral administration of different dose levels of risperidone and 9-hydroxy-risperidone in the brain and other tissues of rat. Psychopharmacology (Berl). 139, 356-363 (1998).
21. Jain KK: Role of nanotechnology in developing new therapies for diseases of the nervous system. Nanomed. 1, 9-12 (2006).
22. Pinto Reis C, Neufeld RJ, Ribeiro AJ et al.: Nanoencapsulation I. Methods for preparation of drug loaded polymeric nanoparticles. Nanomedicine 2, 8-21 (2006).
23. Singh S, Muthu MS: Preparation and characterization of nanoparticles containing an atypical antipsychotic agent. Nanomed. 2, 233-240 (2007).
24. Zili Z, Sfar S, Fessi H: Preparation and characterization of poly-ε-caprolactone nanoparticies containing griseofulvin. Int. J. Pharm 294, 261-267 (2005).
25. Chorny M, Fishbein I, Danenberg HD et al.: Lipophilic drug loaded nanospheres prepared by nanoprecipitation: effect of formulation variables on size, drug recovery and release kinetics. J. Control. Release 83, 389-400 (2002).
26. Moneghini M, Voinovich D, Princivalle F et al.: Formulation and evaluation of vinylpyrrolidone/vinylacetate copolymer microspheres with carbamazepine. Pharma Dev. Tech. 5(3), 347-353 (2000).
27. Verger ML, Fluckiger L, Kim Y et al.: Preparation and characterization of nanoparticles containing an antihypertensive agent. Eur. J. Pharm. Biopharm. 46, 137-143 (1998).
28. Yang SC, Lu LF, Cai Y et al.: Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J. Control. Release 59, 299-307 (1999).
29. Kapur S, VanderSpek SC, Brownlee BA et al.: Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J. Pharmacol. Exp. Ther: 305, 625-631 (2003).
30. Naiker DV, Catts SV, Catts VS et al.: Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat. Eur. J. Pharmacol. 540, 87-90 (2006).
31. Fray PJ, Sahakian, BJ, Robbins TW et al.: An observationall method for quantifying the behavioural effects of dopamine agonists: contrasting effects of d-amphetamine and apomorphine. Psychopharmacology 69, 253-259 (1980).
32. Waddington JL: Psychopharmacological studies in rodents: stereotaxic intracerebral injections and behavioral assessment. In: Working Methods in Neuropharmacology. Joseph MH, Waddington JL (Eds). Manchester University Press, Manchester, UK 1 (1986).
33. Muller RH: In: Charge Determination, Muller RH (Ed.). CRC press, Boca Raton, FL. USA 57-97 (1991).
34. Betancourt T, Brown B, Brannon-Peppas L: Doxorubicin-loaded PLGA nanoparticles by nanoprecipitation: preparation, characterization and in vitro evaluation. Nanomed. 2, 219-232 (2007).
35. Friedrich H, Nada A, Bodmeier R: Solid state and dissolution rate characterization of co-ground mixtures of nifedipine and hydrophilic carriers. Drug. Dev. Ind. Pharm. 31, 719-728 (2005).
36. Lu X, Leng Y: TEM study of calcium phosphate precipitation on bioactive titanium surfaces. Biomaterials 25, 1779-1786 (2004).
37. Kreuter J: Nanoparticles and microparticles for drug and vaccine delivery. J. Anat. 189, 503-505 (1996).
38. Govender T, Riley T, Ehtezazi T et al.: Defining the drug incorporation properties of PLA-PEG nanoparticies. Int. J. Pharm. 199, 95-110 (2000).
39. Washington C: Drug release from microdisperse systems. A critical review. Int. J. Pharm 58, 1-12 (1990).
40. Brigger I, Dubernet C, Couvreur P: Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. 54, 631-651 (2002).
41. Protais P, Costentin J, Schwartz JC: Climbing behaviour induced by apomorphine in mice: a simple test for the study of dopamine receptors in striatum. Psychopharmacology 50, 1-6 (1976).